All articles

Wegovy And Insurance: How Coverage Works For Weight Loss Medication

Wegovy And Insurance: How Coverage Works For Weight Loss Medication


Written by:

MedExpress

Medically reviewed by:

Dr Zoë Lees

Published:

6 March 2026

Reading time: 8 minutes
Wegovy And Insurance: How Coverage Works For Weight Loss Medication

If you’re living with obesity and considering whether weight loss medications like Wegovy (semaglutide) could be the next step for you, chances are you’ve already wondered what it might cost and whether your health insurance covers it.

These GLP-1 treatments are available privately and through the NHS, but the prescription charge will depend on your healthcare provider. In this guide, we’ll explain all you need to know about Wegovy treatment costs, insurance coverage, and alternative treatments that could be more cost-effective.

Article Summary:

  • Wegovy (semaglutide) is a GLP-1-based treatment used for weight loss and obesity management.
  • In the UK, weight loss injections are available on the NHS at the standard prescription price to those who are eligible, but you must be referred into a specialist weight management service.
  • The cost of Wegovy is typically not fully covered by private medical insurance companies such as Bupa, Aviva, AXA Health and Vitality, but policies vary, and some offer discounts on weight loss treatments.

What is Wegovy? 

Wegovy is a brand name of a prescription weight loss medication, containing the active ingredient semaglutide. It’s taken once a week as a self-administered injection, to help those living with obesity and weight-related health conditions lose weight.

The pre-filled pen is injected into the abdomen, thigh, or upper arm, and the dose may increase every four weeks, depending on the rate of weight loss and how well you are tolerating side effects

Understanding Wegovy (semaglutide): A GLP-1 receptor agonist for obesity

Now, for how Wegovy works. A GLP-1 (glucagon-like peptide-1) receptor agonist, it mimics the naturally occurring gut hormone in your body that is released after you eat, called GLP-1. This helps to stabilise your blood sugar levels, as well as reducing your appetite and slowing down digestion. The result? An increased feeling of fullness and a reduction in overall food intake and cravings. [1]

In studies, the medication has shown impressive results. In one clinical trial, patients taking the top dose of Wegovy experienced weight loss of 20.7% in 72 weeks when combined with diet and exercise changes. [2]

The weight management benefits have a positive knock-on effect on heart health, too. A major clinical trial found that Wegovy reduces the risk of heart attack, stroke and death from cardiovascular disease by up to 20% in people with a body mass index (BMI) in the overweight or obese range and pre-existing heart disease. This was true even if they didn’t have diabetes. [3]

Who is eligible for Wegovy prescriptions? 

Wondering if Wegovy is safe for you? To be eligible, you must have a body mass index of 30 or higher, or a BMI of 27 or higher if you also have a weight-related condition (like high blood pressure, type 2 diabetes, or high cholesterol).

The treatment is not a silver bullet, however. Alongside the weight loss injections, healthy lifestyle changes like staying active and eating a reduced-calorie diet must be made to lose the weight and help keep it off long term.

How much does Wegovy cost?

How much Wegovy costs will depend on how you access it. In the UK, it would either be through a GP referral on the NHS, or you would purchase it privately. The price of the weight loss injections is also down to the dose you’re buying and which provider you’re buying it from.

If you are prescribed Wegovy, you’ll start on the lowest dose. This may then be increased every four weeks, so your body can get used to side effects and have time to adjust, until you reach your ‘maintenance dose’. This is the dose you stay on long term, where you can manage side effects comfortably and continue to lose weight at a steady, healthy rate. 

Accessing Wegovy through the NHS

To be prescribed Wegovy through the NHS, you must first be referred to an NHS specialist weight management service and meet the strict eligibility criteria as set out by the National Institute for Health and Care Excellence (NICE). [4] A GP typically handles this referral, so they would be your first port of call. However, there can be longer waiting times to get treatment via this route, so it may be less accessible than going private.

Getting Wegovy through the NHS would mean paying the standard £9.90 prescription charge in England for each injection pen. It’s free in Scotland, Wales, and Northern Ireland, and for those with exemptions.

Private prescriptions for Wegovy 

If you do not meet NHS criteria or would prefer not to wait, Wegovy is available privately for those who meet eligibility criteria through weight management clinics, trusted online providers such as MedExpress, and some high‑street chains. This route can give you faster access to your treatment, and online services give you the convenience of expert guidance from your home.

As you’d expect, the cost of Wegovy on a private prescription will be more, though it depends on the dose. Treatments start from £99.99 a month at MedExpress for those who are eligible, rising to £279.99 a month for the highest dose.

Can you get Wegovy on private health insurance policies?

Private medical insurance in the UK varies depending on the healthcare provider and the individual policy, so there’s no official ‘yes’ or ‘no’ answer here. But while some insurance companies and policies might cover chronic medical conditions, it’s unlikely you would be able to get fully-funded coverage for obesity treatments like Wegovy.

Some comprehensive plans might offer partial coverage, but this is still uncommon. Most policies focus on providing cover for ‘acute’ conditions, rather than chronic weight‑management medication.

However, there is some movement in this. In 2025, Vitality became the first health insurer in the UK to offer customers discounted weight loss treatments for up to a year. Members are able to apply through the app, and if they are eligible (with the usual body mass index criteria required for treatment), they can apply for the medicated weight loss pathway. This includes discounted weight loss injections (such as Wegovy or Mounjaro) for up to 12 months, as well as coaching with a dietitian. [5]

Bupa also has a weight management plan, now extended to insurance customers, which can include access to Wegovy where it’s clinically appropriate. But while it does give you access, it’s effectively a pay-as-you-go system rather than being included in your cover.

If Wegovy isn’t available to you through your health insurer, it’s still worth seeing what is. Many policies cover associated services to support those living with obesity, such as dietitians or other weight management programmes.

If in doubt, get in touch with your insurance provider for bespoke advice about what your policy covers.

Why is insurance coverage for GLP-1s so debated?

It’s all down to the distinction between acute conditions and chronic conditions, which is a fundamental part of the criteria for private health insurance policies.

Private medical insurance is designed to cover unforeseen or short-term health issues and illnesses, rather than pre-existing conditions or long-term medical costs. Most insurers classify GLP-1s as weight loss medications for the management of the chronic condition medical condition of obesity, rather than a medical necessity.

Related medications and lower-cost alternatives

If difficulties with your health insurance coverage are preventing you from accessing Wegovy, you might want to look into other treatment options. Wegovy is the brand name for semaglutide, but, much like grocery shopping, you may be able to find a less expensive solution by seeking out unbranded alternatives. There are also other brands available that work in similar ways, such as Mounjaro, Saxenda and Rybelsus, which will have their own costs attached.

Other weight loss treatments include Orlistat, an oral medication that helps prevent the absorption of fat from the food you eat, which can make it easier to lose weight. The unbranded version is available from £21.99 for two weeks’ supply on MedExpress.

Conclusion

It’s unlikely you will find a health insurance provider in the UK that will cover Wegovy or other GLP-1 weight loss medications, though it’s always worth checking with your individual policy. However, your insurance may cover other treatments that could help with obesity-related illnesses.

Check your own policy wording or call your insurer to confirm what’s covered. Those who are eligible can access Wegovy through the NHS or a private prescription from your chosen health provider.

Find out what treatment is suitable for you with MedExpress.

References

  1. Wegovy 0.25 mg, FlexTouch solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC) - (emc) [Internet]. www.medicines.org.uk. Available from: https://www.medicines.org.uk/emc/product/13799/smpc#gref
  2. ‌Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.Wharton, Sean et al.
  3. The Lancet Diabetes & Endocrinology, Volume 13, Issue 11, 949 - 963‌A. Michael Lincoff, Kirstine Brown‐Frandsen, Colhoun HM, Deanfield J, Emerson SS, Sille Esbjerg, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England Journal of Medicine [Internet]. 2023 Nov 11;389(24). Available from: https://www.nejm.org/doi/10.1056/NEJMoa2307563
  4. ‌National Institute for Health and Care Excellence. Overview | Semaglutide for managing overweight and obesity | Guidance | NICE [Internet]. www.nice.org.uk. 2023. Available from: https://www.nice.org.uk/guidance/ta875
  5. ‌Kollewe J. Health insurer Vitality is first to offer UK members weight-loss jabs [Internet]. the Guardian. The Guardian; 2025. Available from: https://www.theguardian.com/society/2025/feb/12/uk-health-insurer-vitality-to-offer-members-discounted-anti-obesity-drugs

Next scheduled review date: 6 March 2029

Authors

MedExpress Logo

Written by: MedExpress

MedExpress

Dr Zoë Lees

Medically reviewed by: Dr Zoë Lees

Dr Zoe Lees is a medical writer with postdoctoral research experience from the University of Glasgow, where she focused on metabolic complications of pregnancy and the role of adipose tissue (fat tissue) function. Zoe has a specialist interest in medical communications and is dedicated to delivering content of the highest scientific quality, grounded in robust evidence-based research.

Note from the experts

Remember: This blog shouldn’t be regarded as medical advice, diagnosis, or treatment. We make sure everything we publish is fact checked by clinical experts and regularly reviewed, but it may not always reflect the most recent health guidelines. Always speak to your doctor about any health concerns you have.